ArriVent BioPharma, Inc. · NASDAQ:AVBP

ArriVent BioPharma, Inc. financial statements

ArriVent BioPharma, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Revenue0000
Research and development153.4M153.4M79.0M79.0M64.9M64.9M30.4M6.43M
Selling, general and administrative24.2M15.3M9.71M6.47M3.02M
Operating income-177.5M-177.5M-94.3M-94.3M-74.6M-74.6M-36.9M-8.70M
Depreciation and amortization-3.03M3.03M36.9M11.6M
EBITDA-180.6M-174.5M02.90M
Income before tax-166.3M-80.5M-69.3M-36.9M-51.6M
Income tax-80.5M-36.9M-11.6M
Net income-166.3M-166.3M-80.5M-80.5M-69.3M-69.3M-36.9M-51.6M
Earnings per share, basic-4.32-4.32-2.56-2.56-32.38-2.17-1.10-40.44
Earnings per share, diluted-4.32-2.56-32.38

Balance sheet

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Cash and equivalents45.5M45.5M74.3M74.3M150.4M150.4M163.4M37.3M
Short-term investments267.3M267.3M144.6M144.6M0
Receivables60.0K500.0K761.0K500.0K250.0K
Inventory-240.0K
Current assets332.9M332.9M227.0M227.0M160.0M160.0M182.6M43.0M
Total assets333.2M333.2M274.9M274.9M163.1M163.1M182.8M43.0M
Accounts payable5.93M5.93M3.78M3.78M4.53M4.53M3.09M293.0K
Current liabilities25.9M25.9M17.3M17.3M11.6M11.6M8.36M1.82M
Total debt14.0K176.0K317.0K139.0K
Total liabilities25.9M25.9M17.3M17.3M11.8M11.8M8.37M1.82M
Shareholders' equity307.2M307.2M257.7M257.7M-153.2M151.3M174.5M41.2M
Shares outstanding42.5M38.5M33.7M31.5M2.75M32.0M33.5M1.28M

Cash flow

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Cash from operations-160.6M-160.6M-70.2M-70.2M-55.8M-55.8M-43.6M-12.6M
Capital spending00000
Free cash flow-160.6M-70.2M-55.8M-43.6M-12.6M
Cash from investing-71.2M-71.2M-192.5M-192.5M-40.0M
Cash from financing203.1M203.1M186.6M186.6M42.9M42.9M169.7M89.9M
Change in cash-28.8M-28.8M-76.1M-76.1M-13.0M-13.0M126.1M37.3M